Condition: Digestive Cancer · Metastatic Colorectal Cancer · Hepatocellular Carcinoma · Sponsor: UNICANCER
Targeted therapy drug monitoring in digestive oncology: Dosage of plasma levels of various multikinase inhibitors (MKI) in patients treated for advanced digestive cancer (gastrointestinal stromal tumor (GIST), metastatic colorectal cancer (mCRC), hepatocellular carcinoma (HCC), gastroenteropancreatic neuroendocrine tumor (gepNET), or pancreatic neuroendocrine tumor (pNET)), with the aim of determine the optimal dose adapted for each patient, in the future.
This description comes directly from the study's public registry record.
Michaël CHEVROT, Ph.D · +33 (0) 1 71 93 61 61 · m-chevrot@unicancer.fr
Always discuss trial participation with your own doctor first.
| CHU d'Amiens Pcardie - Hopital Sud | Amiens, France | Recruiting |
| CH d'Auxerre | Auxerre, France | Recruiting |
| Institut du Cancer Avignon - Institut Sainte Catherine | Avignon, France | Withdrawn |
| CH de Bayeux - Onconormandie | Bayeux, France | Withdrawn |
| Centre Jean Perrin | Clermont-Ferrand, France | Recruiting |
| Hôpital Beaujon APHP | Clichy, France | Recruiting |
| Centre Georges Francois Leclerc | Dijon, France | Withdrawn |
| Institut de Cancérologie de Bourgogne | Dijon, France | Recruiting |
| CH Eure Seine - Hopital d'Evreux Vernon | Évreux, France | Not Yet Recruiting |
| Centre Oscar Lambret | Lille, France | Recruiting |
| Groupement des hôpitaux de l'Institut Catholique de Lille - Hôpital Saint Vincent de Paul | Lille, France | Not Yet Recruiting |
| Centre Léon Bérard | Lyon, France | Withdrawn |
+ 17 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05443087